Ekopipam

Ekopipam
(IUPAC) ime
	(–)-trans-6,7,7a,8,9,13b-heksahidro-3-hloro-2-hidroksi-N-metil-5H-benzo[d]napto-(2,1-b)azepin
Klinički podaci
Identifikatori
CAS broj	112108-01-7
ATC kod	nije dodeljen
PubChem	107930
UNII	0X748O646K
Hemijski podaci
Formula	C19H20ClNO
Mol. masa	313,821 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C19H20ClNO/c1-21-9-8-13-10-16(20)18(22)11-15(13)19-14-5-3-2-4-12(14)6-7-17(19)21/h2-5,10-11,17,19,22H,6-9H2,1H3/t17-,19+/m0/s1 ; Key: DMJWENQHWZZWDF-PKOBYXMFSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

Ekopipam (SCH-39166) je sintetički benzazepinski derivat. Ovaj lek deluje kao selektivni antagonist D₁/D₅ receptora, sa neznatnim afinitetom za bilo D₂-slične ili 5-HT₂ receptore.^[3] On ispoljava sedativno, antipsihotičko i anoreksno dejstvo. Ovaj lek je bio ispitivan za moguću primenu na ljudima, mada nije odobren zbog nuspojava, kao što su depresija i anksioznost.^[4]^[5]

Hemijska sinteza

Ekopipam se može sintetisati iz jednostavnog derivata tetralina:^[6]

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Chipkin RE, Iorio LC, Coffin VL, McQuade RD, Berger JG, Barnett A (December 1988). „Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity”. The Journal of Pharmacology and Experimental Therapeutics 247 (3): 1093–102. PMID 2905002.
↑ Hou D, Schumacher D (November 2001). „The selection of a commercial route for the D1 antagonist Sch-39166”. Current Opinion in Drug Discovery & Development 4 (6): 792–9. PMID 11899619.
↑ Astrup A, Greenway FL, Ling W, Pedicone L, Lachowicz J, Strader CD, Kwan R (July 2007). „Randomized controlled trials of the D1/D5 antagonist ecopipam for weight loss in obese subjects”. Obesity (Silver Spring, Md.) 15 (7): 1717–31. DOI:10.1038/oby.2007.205. PMID 17636090.
↑ Hou, D; Schumacher, D (2001). „The selection of a commercial route for the D1 antagonist Sch-39166.”. Current opinion in drug discovery & development 4 (6): 792–9. PMID 11899619.

	Portal Medicina
	Portal Hemija